** Shares of developer Roivant ROIV.O up 8.8% at $23 premarket

** Co says in a mid‑stage trial, brepocitinib improved symptoms of cutaneous sarcoidosis — a rare skin disease caused by inflammation that forms painful lumps under the skin

**  Higher dose improved disease activity scores by about 22 points over 16 weeks vs about 1 point for placebo, co says

**  More than half of treated patients reached functional remission, per investigator Dr. Misha Rosenbach

**  Co to start late-stage trial in 2026 after talks with U.S. FDA

** Shares up ~83% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))